One of the missions of the CHTN is to provide investigators with high quality research material and opportunities! As a result, the CHTN would like to support and invite you to participate in the University Hospitals (UH) Research and Education Institute virtual event, UH Research & Innovation Day - Exploring New Frontiers in Brain Health. We hope that you take the opportunity to register for the meeting and share the opportunity with your colleagues to connect with other researchers.
What: Exploring New Frontiers in Brain Health
When: Thursday, October 29th, 2020
For the last 32 years, former CHTN Southern Division Principal Investigator (PI), Dr. William Grizzle, and Division Coordinator, Kathy Sexton, dedicated their professional lives to improving the world of biorepository sciences and assisting the research community by establishing and growing the CHTN into the most reliable biospecimen resource for the scientific community. In 1987, the CHTN Southern Division, formerly located at The University of Alabama at Birmingham (UAB), was awarded one of the first of the three original CHTN grants from the National Cancer Institute (NCI).
Although the CHTN is happy to report the NCI agreed to support the highly valuable resource for another five-year funding cycle, the CHTN Southern Division has changed locations and is now located at Duke University. This means we have to say good-bye to two of the founding members of the CHTN, Kathy Sexton and Dr. Bill Grizzle.
In addition to his responsibilities as a board-certified... Read more
At least two "valleys of death" have been identified in the spectrum of biomedical research where blockage occurs in translating advances in scientific knowledge to clinical practice and decision making1. One "valley" is the translation of basic scientific knowledge to create new diagnostic techniques or therapeutic interventions that can be used in the care of patients. The analysis of human biospecimens can help cross these barriers. The analysis of biospecimens are used to either confirm the biochemical/biophysical/genetic mechanisms of disease or to test biospecimens in the workup of new diagnostic procedures or confirmation of biological outcomes of therapeutic interventions. It is the difficulty and expense in obtaining appropriate groups of human biospecimens to do such studies that contribute greatly to the obstacles in advancing biomedical research.
Does your biospecimen resource impact science like this?
Why Biobank? A recent article was published explaining why there are many names scientists often suggest as an alternative to the word “biobank.” In his article, Biobanks: Why All the Names, Robert Hewitt wrote that biobanks are not meeting the expectations of patients, researchers and the society as a whole1.
Reasons for Dr. Hewitt’s perception are indicated as such. Retrospectively collected biospecimens, which exist in most biobanks, may not meet the requirements of the studies of the researchers. Additionally, the consent forms patients sign for the use of their biospecimens may not cover the proposed research. Finally, a highly selective review process can delay the release of biospecimens from the biobank.
A different author, Dominic Allen, once wrote biobanks should collect biospecimens prospectively in a trusted collection of networks2 to overcome some of these limitations. Fortunately, the Cooperative Human Tissue Network’s (CHTN) founders had the foresight... Read more
- 1 of 3
- next ›